Alert: Major Price Advance (3/4/20)-Pacific Biosciences of Californi (NASDAQ: PACB).


Pacific Biosciences of Californi (NASDAQ: PACB) stock enjoyed a major increase of 10.9% on 3/4/20. The shares closed at $3.86. Moreover, exceptionally high trading volume at 202% of normal accompanied the advance. The stock has risen 3.5% during the last week but has been weak relative to the market over the last nine months.


Current PriceTarget Research Rating

PACB’s future returns on capital are forecasted to be below the cost of capital. Accordingly, the company is expected to be a major Value Eraser.

PACB has a current Value Trend Rating of F (Lowest Rating). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. PACB has a very low Power Rating of 12 and a very low Appreciation Score of 4, producing the Lowest Value Trend Rating.

Rating Review

In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.

About John Lafferty 101900 Articles
During his career, John has developed valuation and stock rating methodologies, managed institutional portfolios and mutual funds, and provided equity research to institutional investors on thousands of companies. He has been Director of Research at PTR since its inception in 2004.

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.